Role of the gut microbiome in nonalcoholic fatty liver disease

Nutrition in Clinical Practice

Volumn 30, Issue 6, 2015, Pages 780-786

  Aqel, Bashar ^a   DiBaise, John K ^a  

^a MAYO CLINIC   (United States)

Author keywords

cytokines; fatty acids; fatty liver; liver disease; microbiota; nonalcoholic fatty liver disease; obesity; organ transplantation; probiotics

Indexed keywords

INFLAMMASOME;

DISEASE COURSE; DYSBIOSIS; FATTY LIVER; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; LIPID STORAGE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; REVIEW; MICROBIOLOGY; RISK FACTOR;

GASTROINTESTINAL MICROBIOME; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84946749728     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533615605811     Document Type: Review

References (46)

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142 (7): 1592-1609.
2. Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012; 91 (6): 319-327.
3. Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A,. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism. 2013; 62 (3): 352-360.
4. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40 (6): 1387-1395.
5. Browning JD, Cohen JC, Hobbs HH,. Patatin-like phospholipase domain-containing 3 and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology. 2010; 52 (4): 1189-1192.
6. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI,. The human microbiome project. Nature. 2007; 449 (7164): 804-810.
7. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011; 473 (7346): 174-180.
8. Strowig T, Henao-Mejia J, Elinav E, Flavell R,. Inflammasomes in health and disease. Nature. 2012; 481 (7381): 278-286.
9. Delzenne NM, Cani PD,. Gut microbiota and the pathogenesis of insulin resistance. Curr Diab Rep. 2011; 11 (3): 154-159.
10. Krajmalnik-Brown R, Ilhan ZE, Kang DW, DiBaise JK,. Effects of gut microbes on nutrient absorption and energy regulation. Nutr Clin Pract. 2012; 27 (2): 201-214.
11. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012; 143 (4): 913-916, e917.
12. Stepanova M, Rafiq N, Younossi ZM,. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010; 59 (10): 1410-1415.
13. Takaki A, Kawai D, Yamamoto K,. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013; 14 (10): 20704-20728.
14. Day CP, James OF,. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998; 114 (4): 842-845.
15. Malhi H, Gores GJ,. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 2008; 28 (4): 360-369.
16. Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A. 2006; 103 (3): 732-737.
17. Diamant M, Blaak EE, de Vos WM,. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev. 2011; 12 (4): 272-281.
18. Compare D, Coccoli P, Rocco A, et al. Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2012; 22 (6): 471-476.
19. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009; 49 (6): 1877-1887.
20. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008; 48 (6): 993-999.
21. Ma J, Fox CS, Jacques PF, et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol. 2015; 63 (2): 462-469.
22. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010; 51 (6): 1961-1971.
23. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008; 138 (8): 1452-1455.
24. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M,. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007; 47 (4): 571-579.
25. Kubes P, Mehal WZ,. Sterile inflammation in the liver. Gastroenterology. 2012; 143 (5): 1158-1172.
26. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482 (7384): 179-185.
27. Henao-Mejia J, Elinav E, Strowig T, Flavell RA,. Inflammasomes: far beyond inflammation. Nat Immunol. 2012; 13 (4): 321-324.
28. Ghoshal S, Witta J, Zhong J, de Villiers W, Eckhardt E,. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res. 2009; 50 (1): 90-97.
29. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56 (7): 1761-1772.
30. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003; 37 (2): 343-350.
31. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG,. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001; 48 (2): 206-211.
32. Shanab AA, Scully P, Crosbie O, et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with Toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci. 2011; 56 (5): 1524-1534.
33. Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013; 58 (1): 120-127.
34. Raman M, Ahmed I, Gillevet PM, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013; 11 (7): 868-875, e861-e863.
35. Mencarelli A, Distrutti E, Renga B, et al. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One. 2011; 6 (7): e22978.
36. Mencarelli A, Cipriani S, Renga B, et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One. 2012; 7 (9): e45425.
37. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. 2009; 49 (3): 989-997.
38. Wong VW, Won GL, Chim AM, et al. Treatment of nonalcoholic steatohepatitis with probiotics: a proof-of-concept study. Ann Hepatol. 2013; 12 (2): 256-262.
39. Malaguarnera M, Vacante M, Antic T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012; 57 (2): 545-553.
40. Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014; 39 (11): 1276-1285.
41. Ferolla SM, Armiliato GN, Couto CA, Ferrari TC,. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015; 7 (3): 559-565.
42. Daubioul CA, Taper HS, De Wispelaere LD, Delzenne NM,. Dietary oligofructose lessens hepatic steatosis, but does not prevent hypertriglyceridemia in obese zucker rats. J Nutr. 2000; 130 (5): 1314-1319.
43. Kok N, Roberfroid M, Delzenne N,. Dietary oligofructose modifies the impact of fructose on hepatic triacylglycerol metabolism. Metabolism. 1996; 45 (12): 1547-1550.
44. Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM,. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr. 2005; 59 (5): 723-726.
45. Li JV, Reshat R, Wu Q, et al. Experimental bariatric surgery in rats generates a cytotoxic chemical environment in the gut contents. Front Microbiol. 2011; 2: 183.
46. Liou AP, Paziuk M, Luevano JM Jr., Machineni S, Turnbaugh PJ, Kaplan LM,. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013; 5 (178):178ra141.